1例2019冠状病毒病患者出现氯喹诱导的尖端扭转型室速 - Suppr

Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.

作者信息

Szekely Yishay, Lichter Yael, Shrkihe Bander Abu, Bruck Hila, Oster Howard S, Viskin Sami

机构信息

Department of Cardiology, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Department of Intensive Care, Sourasky Tel Aviv Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

出版信息

Heart Rhythm. 2020 Sep;17(9):1452-1455. doi: 10.1016/j.hrthm.2020.04.046. Epub 2020 May 5.

DOI:10.1016/j.hrthm.2020.04.046

PMID:32380291

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7198423/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8803/7198423/b9e1384af24d/gr1_lrg.jpg

相似文献

Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.1例2019冠状病毒病患者出现氯喹诱导的尖端扭转型室速

Heart Rhythm. 2020 Sep;17(9):1452-1455. doi: 10.1016/j.hrthm.2020.04.046. Epub 2020 May 5.

QT prolongation, torsades de pointes, and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: A systematic review.QT 间期延长、尖端扭转型室性心动过速和 COVID-19 短期使用氯喹或羟氯喹导致的猝死：系统评价。

Heart Rhythm. 2020 Sep;17(9):1472-1479. doi: 10.1016/j.hrthm.2020.05.008. Epub 2020 May 11.

QT Interval Control to Prevent Torsades de Pointes during Use of Hydroxychloroquine and/or Azithromycin in Patients with COVID-19.在新冠肺炎患者使用羟氯喹和/或阿奇霉素期间控制QT间期以预防尖端扭转型室速

Arq Bras Cardiol. 2020 Jun;114(6):1061-1066. doi: 10.36660/abc.20200389. Epub 2020 Jul 3.

Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.对社论《心血管疾病患者的COVID-19》的回应：使用羟氯喹或氯喹及阿奇霉素治疗COVID-19：尖端扭转型室速的潜在风险。

Arch Cardiovasc Dis. 2020 May;113(5):367-368. doi: 10.1016/j.acvd.2020.04.001. Epub 2020 Apr 15.

Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment.探索性 COVID-19 治疗中药物相互作用对 QTc 间期的影响因素。

Heart Rhythm. 2020 Jul;17(7):e231-e232. doi: 10.1016/j.hrthm.2020.04.016. Epub 2020 Apr 14.

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。

Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.

Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.氯喹、羟氯喹和阿奇霉素对 SARS-CoV-2 感染患者校正 QT 间期的影响。

Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.

Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.COVID-19 药物治疗的心脏安全性：综述及建议监测方案。

Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215-221. doi: 10.1177/2048872620922784. Epub 2020 May 6.

Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.氯喹和羟氯喹在2019冠状病毒病中的应用及其心血管影响：理解安全性差异以改进临床试验的解读与设计

Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008688. doi: 10.1161/CIRCEP.120.008688. Epub 2020 May 21.

QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin.COVID-19 患者接受羟氯喹/阿奇霉素治疗后出现 QT 间期延长和尖端扭转型室性心动过速。

Heart Rhythm. 2020 Sep;17(9):1425-1433. doi: 10.1016/j.hrthm.2020.05.014. Epub 2020 May 12.

引用本文的文献

Clinical implications of COVID-19 in patients with metabolic-associated fatty liver disease.COVID-19 对代谢相关脂肪性肝病患者的临床影响。

World J Gastroenterol. 2023 Jan 21;29(3):487-502. doi: 10.3748/wjg.v29.i3.487.

Chronic Administration of COVID-19 Drugs Fluvoxamine and Lopinavir Shortens Action Potential Duration by Inhibiting the Human Ether-à-go-go-Related Gene and Cav1.2.长期服用新冠药物氟伏沙明和洛匹那韦可通过抑制人类去极化相关基因和Cav1.2来缩短动作电位时程。

Front Pharmacol. 2022 Jul 7;13:889713. doi: 10.3389/fphar.2022.889713. eCollection 2022.

QT Interval Prolongation Is a Novel Predictor of 1-Year Mortality in Patients With COVID-19 Infection.QT间期延长是新冠病毒感染患者1年死亡率的新型预测指标。

Front Cardiovasc Med. 2022 Jun 9;9:869089. doi: 10.3389/fcvm.2022.869089. eCollection 2022.

ECG changes in hospitalised patients with COVID-19 infection.新型冠状病毒肺炎（COVID-19）感染住院患者的心电图变化。

Br J Cardiol. 2021 Jun 2;28(2):24. doi: 10.5837/bjc.2021.024. eCollection 2021.

Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.新型冠状病毒肺炎患者与非新型冠状病毒肺炎患者短期口服氯喹和羟氯喹治疗的安全性：一项系统评价

Pharmaceuticals (Basel). 2022 May 21;15(5):634. doi: 10.3390/ph15050634.

Safety profile of COVID-19 drugs in a real clinical setting.在真实临床环境中 COVID-19 药物的安全性概况。

Eur J Clin Pharmacol. 2022 May;78(5):733-753. doi: 10.1007/s00228-021-03270-2. Epub 2022 Jan 28.

ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up.ESC 指导意见：COVID-19 大流行期间心血管疾病的诊断和管理：第 2 部分——治疗途径、治疗和随访。

Cardiovasc Res. 2022 Jun 22;118(7):1618-1666. doi: 10.1093/cvr/cvab343.

Eur Heart J. 2022 Mar 14;43(11):1059-1103. doi: 10.1093/eurheartj/ehab697.

Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.新型冠状病毒肺炎潜在抗病毒治疗药物与hERG钾通道孔道之间的相互作用研究——一种药物抗靶点

Front Cardiovasc Med. 2021 May 4;8:645172. doi: 10.3389/fcvm.2021.645172. eCollection 2021.

Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.建模 2019 年冠状病毒病患者的心脏性猝死风险因素：羟氯喹和阿奇霉素的案例。

Europace. 2021 Jul 18;23(7):1124-1133. doi: 10.1093/europace/euab043.

本文引用的文献

The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.接受羟氯喹和阿奇霉素治疗的新冠肺炎患者的QT间期。

Nat Med. 2020 Jun;26(6):808-809. doi: 10.1038/s41591-020-0888-2.

Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19).急件：针对新型冠状病毒病（COVID-19）可能的药物治疗的 QTc 延长和致扭转型心动过速的潜在风险的应对和规避指导建议。

Mayo Clin Proc. 2020 Jun;95(6):1213-1221. doi: 10.1016/j.mayocp.2020.03.024. Epub 2020 Apr 7.

Chloroquine for SARS-CoV-2: Implications of Its Unique Pharmacokinetic and Safety Properties.氯喹治疗 2019 新型冠状病毒病：独特的药代动力学和安全性特征的影响。

Clin Pharmacokinet. 2020 Jun;59(6):659-669. doi: 10.1007/s40262-020-00891-1.

Chloroquine and hydroxychloroquine in covid-19.氯喹和羟氯喹在2019冠状病毒病中的应用

BMJ. 2020 Apr 8;369:m1432. doi: 10.1136/bmj.m1432.

Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.探索性新冠肺炎治疗中药物相互作用对QTc的影响因素

Circulation. 2020 Jun 16;141(24):e906-e907. doi: 10.1161/CIRCULATIONAHA.120.047521. Epub 2020 Apr 8.

SARS-CoV-2, COVID-19, and inherited arrhythmia syndromes.严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）、COVID-19 与遗传性心律失常综合征。

Heart Rhythm. 2020 Sep;17(9):1456-1462. doi: 10.1016/j.hrthm.2020.03.024. Epub 2020 Mar 31.

Chloroquine for the 2019 novel coronavirus SARS-CoV-2.氯喹用于2019新型冠状病毒SARS-CoV-2。

Int J Antimicrob Agents. 2020 Mar;55(3):105923. doi: 10.1016/j.ijantimicag.2020.105923. Epub 2020 Feb 15.

Cardiac arrhythmia considerations of hormone cancer therapies.激素癌症疗法的心律失常考虑因素。

Cardiovasc Res. 2019 Apr 15;115(5):878-894. doi: 10.1093/cvr/cvz020.

The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review.奎宁和结构相关抗疟药物的致心律失常性心脏毒性：系统评价。

BMC Med. 2018 Nov 7;16(1):200. doi: 10.1186/s12916-018-1188-2.

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients.预测住院患者QT间期延长风险评分的开发与验证

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):479-87. doi: 10.1161/CIRCOUTCOMES.113.000152. Epub 2013 May 28.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chloroquine-induced torsades de pointes in a patient with coronavirus disease 2019.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献